Phaseline

Targets › IL1

IL1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2029.

Open in Phaseline: the race on IL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GenascenceGNSC-001
AAV2.5-mediated IL-1Ra gene therapy
IL1Phase 1Osteoarthritis, KneeMay 2029

Conditions

Osteoarthritis, Knee (1)

Modalities

mixed (1)

Companies

Genascence (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.